Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Extranodal natural killer/T-cell lymphoma, nasal type (NKTCL) is a highly aggressive
peripheral T-cell lymphoma (PTCL). Patients with newly diagnosed stage IV and
relapsed/refractory have poor prognosis. 5-year progression-free survival was reported only
55%. Chidamide is a selective histone deacetylase inhibitor which was approved by FDA in
treating relapsed or refractory PTCL. In phase I and II studies of chidamide, patients with
relapsed or refractory NKTCL achieved a higher overall remission. Patients who obtained
complete or partial remission had much favourable duration of remission. Thus, the invesgator
design this study to evaluate the role of maintenance treatment of chidamide for induction
chemotherapy-responded newly-diagnosed advanced and relapsed/refractory NKTCL patients.